Sabra Health Care REIT Q1 revenue rises to $221.8 million; reiterates 2026 guidance
Sabra reported first quarter 2026 results, with total revenues of $221.8 million, up from $183.5 million a year earlier, and normalized FFO of $0.38 per diluted share, up from $0.35. Net income attributable to Sabra fell to $0.16 per diluted share from $0.17, and the company reiterated its full-year 2026 guidance and declared a $0.30 quarterly dividend.
Key points
- Total revenues were $221.8 million for Q1 2026, compared with $183.5 million in Q1 2025.
- Normalized FFO was $0.38 per diluted share, compared with $0.35; normalized AFFO was $0.39, compared with $0.37.
- Net income attributable to Sabra was $40.9 million, or $0.16 per diluted share, compared with $40.3 million, or $0.17, a year earlier.
- The board declared a $0.30 quarterly dividend payable May 29, 2026, to holders of record on May 15, 2026; full-year 2026 guidance was reiterated.
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.